In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- HIV infected people have higher age-related illness riskon August 17, 2019 at 4:49 am
According to a new study, people who have been living with HIV have higher chances of being affected by diseases and illnesses, a few of which are commonly associated with ageing. Data from 20 ...
- HIV-positive man sues Louisiana police department over rescinded job offeron August 16, 2019 at 5:11 pm
A January trial date has been set in a lawsuit accusing a Louisiana sheriff of rescinding a job offer to an applicant who is HIV-positive. William “Liam” Pierce sued Iberia Parish Sheriff Louis Ackal ...
- Would-be deputy, HIV-positive, suing over lost job offeron August 16, 2019 at 2:40 pm
LAFAYETTE, La. — A January trial date has been set in a lawsuit accusing a Louisiana sheriff of rescinding a job offer to an applicant who is HIV-positive. William “Liam” Pierce sued Iberia Parish ...
- A Tissue Sample From 1966 Held Traces of Early HIVon August 16, 2019 at 11:48 am
In 1966, a 38-year-old man visited a hospital in what is now the Democratic Republic of Congo. His name, his symptoms, and everything about him beyond his age and gender have been lost to history. But ...
- Ending the HIV/AIDS Epidemic Only Happens if Black America Leadson August 16, 2019 at 10:57 am
In 2011, Science Magazine’s “Breakthrough of the Year” was the discovery that antiretroviral drugs were a game changer in HIV prevention. The development of treatment as Prevention and Pre-Exposure ...
- Analysis of the TCR Repertoire in HIV-Exposed but Uninfected Infantson August 16, 2019 at 4:20 am
Maternal human immunodeficiency virus (HIV) infection has been shown to leave profound and lasting impacts on the HIV-exposed uninfected (HEU) infant, including increased mortality and morbidity, ...
- Ending HIV: National coalition brings big money to the crisis in the Southon August 16, 2019 at 3:02 am
A new push to end the HIV epidemic — with big money behind it — is underway and South Florida has a lot at stake. The Miami-Dade/Broward/Palm Beach area has the highest HIV rate of new diagnosis per ...
- Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximabon August 16, 2019 at 2:07 am
The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a ...
- Injection Practices and Sexual Behaviors Among Persons With Diagnosed HIV Infection Who Inject Drugs — United States, 2015–2017on August 15, 2019 at 9:18 pm
Morbidity and Mortality Weekly Report. 2019;68(30):653-657. MMP uses a two-stage sampling method. In the first stage, 23 jurisdictions are sampled from all U.S. states, the District of Columbia, and ...
- HIV/AIDS a "crisis” in the South, national coalition sayson August 15, 2019 at 2:31 pm
Daniel Downer grew up in Apopka as a preacher’s kid, a ‘PK’ as he calls it. Faith was the anchor in his home and his community. When it came to sex, conversations were limited. “The only two things ...
via Google News and Bing News